Analyse économique de l’administration d’une chimiothérapie en hospitalisation à domicile (HAD) comparée à l’hospitalisation de jour dans les cancers bronchopulmonaires non à petites cellules de stade IV

Vergnenègre, A.; Decroisette, C.; Vincent, François; Dalmay, François; Melloni, B.; Bonnaud, F; Eichler, B

doi:10.1016/s0761-8425(06)71575-3

Cited by 11 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Savings for chemotherapy administered at home has also been demonstrated in solid tumors like colorectal, non-small cell lung cancer with a decrease in expenses of up to 53 % for intensive chemotherapies mainly administered for hematological malignancies [4, 5, 17]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Touati

Lamarsalle²,

Moreau

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

At home injectable chemotherapy for patients receiving treatment for hematological diseases is still in debate. Given the expense of new innovative medicines, at home treatment has been proposed as a suitable option for improving patient quality of life and decreasing treatment costs. We decided to assess the cost of bortezomib administration in France among multiple myeloma patients from an economic standpoint. Patients in this study were treated within a regional hematological network combining outpatient hospital care and Hospital care at Home administration. To make the cost comparison, our team simulated outpatient hospital care expenses. Fifty-four consecutive multiple myeloma patients who received at least one injection of bortezomib in Hospital care at Home from January 2009 to December 2011 were included in the study. The median number of injections was 12 (range 1–44) at home and 6 (range 0–30) in the outpatient care unit. When compared with the cost simulation of outpatient hospital care alone, bortezomib administration with combined care was significantly less expensive for the National Health Insurance (NHI) budget. The mean total cost per patient and per injection was 954.20 € for combined outpatient and Hospital care at Home vs 1143.42 € for outpatient hospital care alone. This resulted in an estimated 16.5 % cost saving (Wilcoxon signed-rank test, p < 0.0001). The greatest savings were observed in administration costs (37.5 % less) and transportation costs (68.1 % less). This study reflects results for a regionally implemented program for multiple myeloma patients treated with bortezomib in routine practice in a large rural area.Electronic supplementary materialThe online version of this article (doi:10.1007/s00520-016-3363-3) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Two studies of home injectable chemotherapy have been led in France for solid tumors [4] as well as for malignant hemopathies. There was a recent study published by the team in Nantes on cost benefits of bortezomib administration at home for the multiple myeloma patients [5].…”

Section: Introductionmentioning

confidence: 99%

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Touati

Lamarsalle²,

Moreau

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Leff et al 2005;Barcala et al 2006;H. Anderson et al 2003;Oterino-de-la-Fuente et al 1998;Launois & Perrocheau 1996;Coast et al 1998;Vergnenègre et al 2006;Frick et al 2009;C. Anderson et al 2000).…”

Section: Economic Stakeunclassified

“…From the insurance point of view, HAH is interesting in some studies (Chataway et al, 2006;Leff et al, 2005;Barcala et al, 2006;Anderson et al, 2000Anderson et al, , 2003Oterino-de-la-Fuente et al, 1998;Launois and Perrocheau, 1996;Coast et al, 1998;Vergnenègre et al, 2006;Frick et al, 2009). In some cases the economic pertinence of HAH compared to traditional hospitalization depends on patients' health status and disease gravity (Borras et al, 2001;Goulet et al, 2001).…”

Section: Economic Stakementioning

confidence: 99%

Economic comparison between Hospital at Home and traditional hospitalization using a simulation‐based approach

Verjan

Augusto

Xie

et al. 2013

Journal of Enterprise Information Management

View full text Add to dashboard Cite

1Hospital At Home (HAH) is a concept slowly expanding over time. At first this type of organization was used to accomplish lowtechnical tasks. The main objective was to increase bed availability in hospitals for new patients. Nowadays, HAH structures are able to undertake more technical complex care such as (but not limited to) endof-life care, chemotherapy and rehabilitation. This article accomplishes two main objectives: (i) in the first part we propose a comprehensive literature review dealing with the comparison between traditional hospital and home care structures from an economic standpoint, showing that results are highly dependent on initial conditions of the study (patient health state, territory settings, bio-medical parameters); (ii) in the second part we propose an unbiased economic comparison approach between health care provided in traditional hospital and home care network using formal modeling with Petri nets and discrete event simulation. As an example for the comparison a multi-session treatment is proposed. Various scenarios are tested to ensure that results will be maintained even if initial conditions change. Relevant performance indicators used for comparison are economic costs from the point of view of the insurance and economic costs related to the consumption of resources. This work was founded by the Rhône-Alpes region in France as a part of OSAD project.1

show abstract

“…Home-based chemotherapy offers an alternative to hospitalisation which aims at improving the patient's satisfaction, quality of life [1][2][3][4] and reduce costs [5,6]. In France, its development has been encouraged by recent governmental policy [7,8].…”

Section: Introductionmentioning

confidence: 99%

Stability of antineoplastic agents in use for home-based intravenous chemotherapy

et al. 2008

View full text Add to dashboard Cite

Considering the lack of data about cytotoxic drugs stability provided by the pharmaceutical companies and the difficulties in retrieving and interpreting the literature data, a consensus on the stability of cytotoxic drug preparations is essential for the current practice. With this approach, initiated for home hospitalisation, we propose in this study an initiative of the standardisation of stability data which offers a decision support for other centres.

show abstract

Analyse économique de l’administration d’une chimiothérapie en hospitalisation à domicile (HAD) comparée à l’hospitalisation de jour dans les cancers bronchopulmonaires non à petites cellules de stade IV

Cited by 11 publications

References 10 publications

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Economic comparison between Hospital at Home and traditional hospitalization using a simulation‐based approach

Stability of antineoplastic agents in use for home-based intravenous chemotherapy

Contact Info

Product

Resources

About